← All stocks

Enliven Therapeutics, Inc.

ELVN Net selling
CIK 0001672619 #1481 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$76.51M
$9.19M on a plan · $15.34M straight out of an exercise
Sold at will
$51.98M
7 of 79 sales
Net
−$76.51M
−$51.98M against sales at will

By person

10 insiders · 81 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
ORBIMED ADVISORS LLC entity
10% owner
$51.68M (6)
−$51.68M
6,555,102
8.95%
$389.02M
−14.8%
Derynck Mika K
Director
$9.56M (1) scheduled
−$9.56M
0
0.0000%
$0.00
Collins Helen Louise
CHIEF MEDICAL OFFICER
$5.14M (21) scheduled
−$5.14M
25,000
0.0341%
$1.48M
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
$5.04M (15) scheduled
−$5.04M
758,938
1.04%
$45.04M
−29.6%
Patel Anish
CHIEF OPERATING OFFICER
$1.74M (7) scheduled
−$1.74M
235,011
0.3207%
$13.95M
−31.7%
Hohl Benjamin
CHIEF FINANCIAL OFFICER
$1.30M (12) scheduled
−$1.30M
40,036
0.0546%
$2.38M
Kunkel Lori Anne
Director
$850.25K (5) scheduled
−$850.25K
41,884
0.0572%
$2.49M
−8.8%
Kintz Samuel
PRESIDENT AND CEO
$785.43K (6) scheduled
−$785.43K
890,392
1.22%
$52.84M
−15.0%
Heyman Richard A.
Director
$413.38K (6) scheduled
−$413.38K
146,320
0.1997%
$8.68M
−13.4%
Ballal Rahul D.
Director
22,341
0.0305%
$1.33M
0.0%
Insider
Date
Role
Action
Shares
Price
Amount
Collins Helen Louise
17 Aug 2026
CHIEF MEDICAL OFFICER
Sold after exercise
1,100
$59.35
$65.28K
Collins Helen Louise
17 Aug 2026
CHIEF MEDICAL OFFICER
Sold after exercise
3,900
$58.37
$227.65K
Hohl Benjamin
17 Aug 2026
CHIEF FINANCIAL OFFICER
Sold on a plan
1,388
$59.35
$82.38K
Hohl Benjamin
17 Aug 2026
CHIEF FINANCIAL OFFICER
Sold on a plan
4,630
$58.35
$270.17K
Derynck Mika K
4 Aug 2026
Director
Sold after exercise
158,795
$60.21
$9.56M
Collins Helen Louise
17 Jul 2026
CHIEF MEDICAL OFFICER
Sold after exercise
63
$53.92
$3.40K
Collins Helen Louise
17 Jul 2026
CHIEF MEDICAL OFFICER
Sold after exercise
2,184
$53.42
$116.67K
Collins Helen Louise
17 Jul 2026
CHIEF MEDICAL OFFICER
Sold after exercise
2,063
$52.39
$108.08K
Collins Helen Louise
17 Jul 2026
CHIEF MEDICAL OFFICER
Sold after exercise
459
$51.55
$23.66K
Collins Helen Louise
17 Jul 2026
CHIEF MEDICAL OFFICER
Sold after exercise
231
$50.05
$11.56K
Hohl Benjamin
17 Jul 2026
CHIEF FINANCIAL OFFICER
Sold after exercise
123
$53.87
$6.63K
Hohl Benjamin
17 Jul 2026
CHIEF FINANCIAL OFFICER
Sold after exercise
2,638
$53.38
$140.82K
Hohl Benjamin
17 Jul 2026
CHIEF FINANCIAL OFFICER
Sold after exercise
2,564
$52.32
$134.14K
Hohl Benjamin
17 Jul 2026
CHIEF FINANCIAL OFFICER
Sold after exercise
369
$51.48
$19.00K
Hohl Benjamin
17 Jul 2026
CHIEF FINANCIAL OFFICER
Sold after exercise
324
$49.97
$16.19K
Kunkel Lori Anne
6 Jul 2026
Director
Sold on a plan
5,889
$50.84
$299.42K
Kunkel Lori Anne
6 Jul 2026
Director
Sold on a plan
4,111
$49.98
$205.48K
ORBIMED ADVISORS LLC
22 Jun 2026
10% owner
Sell indirect
46,776
$45.00
$2.10M
ORBIMED ADVISORS LLC
22 Jun 2026
10% owner
Sell indirect
787,024
$45.38
$35.72M
ORBIMED ADVISORS LLC
22 Jun 2026
10% owner
Sell indirect
1,477
$45.00
$66.47K
ORBIMED ADVISORS LLC
22 Jun 2026
10% owner
Sell indirect
24,846
$45.38
$1.13M
Collins Helen Louise
17 Jun 2026
CHIEF MEDICAL OFFICER
Sold after exercise
1,133
$44.74
$50.69K
Collins Helen Louise
17 Jun 2026
CHIEF MEDICAL OFFICER
Sold after exercise
2,599
$43.87
$114.02K
Collins Helen Louise
17 Jun 2026
CHIEF MEDICAL OFFICER
Sold after exercise
1,268
$42.83
$54.30K
Hohl Benjamin
17 Jun 2026
CHIEF FINANCIAL OFFICER
Sold after exercise
1,238
$44.75
$55.40K
Hohl Benjamin
17 Jun 2026
CHIEF FINANCIAL OFFICER
Sold after exercise
3,401
$43.86
$149.18K
Hohl Benjamin
17 Jun 2026
CHIEF FINANCIAL OFFICER
Sold after exercise
1,379
$42.79
$59.00K
ORBIMED ADVISORS LLC
15 Jun 2026
10% owner
Sell indirect
272,322
$45.02
$12.26M
ORBIMED ADVISORS LLC
15 Jun 2026
10% owner
Sell indirect
9,086
$45.02
$409.05K
Kunkel Lori Anne
5 Jun 2026
Director
Sold on a plan
354
$35.82
$12.68K
Kunkel Lori Anne
5 Jun 2026
Director
Sold on a plan
1,867
$35.36
$66.01K
Kunkel Lori Anne
5 Jun 2026
Director
Sold on a plan
7,779
$34.28
$266.66K
Collins Helen Louise
18 May 2026
CHIEF MEDICAL OFFICER
Sold after exercise
223
$41.21
$9.19K
Collins Helen Louise
18 May 2026
CHIEF MEDICAL OFFICER
Sold after exercise
1,302
$40.25
$52.40K
Collins Helen Louise
18 May 2026
CHIEF MEDICAL OFFICER
Sold after exercise
3,475
$39.53
$137.38K
Collins Helen Louise
17 Apr 2026
CHIEF MEDICAL OFFICER
Sold after exercise
2,441
$48.06
$117.30K
Collins Helen Louise
17 Apr 2026
CHIEF MEDICAL OFFICER
Sold after exercise
2,419
$47.39
$114.64K
Collins Helen Louise
17 Apr 2026
CHIEF MEDICAL OFFICER
Sold after exercise
140
$45.81
$6.41K
Collins Helen Louise
25 Mar 2026
CHIEF MEDICAL OFFICER
Sold after exercise
40,000
$35.10
$1.40M
Collins Helen Louise
17 Mar 2026
CHIEF MEDICAL OFFICER
Sold after exercise
5,000
$27.76
$138.80K
Collins Helen Louise
10 Mar 2026
CHIEF MEDICAL OFFICER
Sold after exercise
10,129
$30.19
$305.83K
Collins Helen Louise
9 Mar 2026
CHIEF MEDICAL OFFICER
Sold after exercise
29,871
$30.02
$896.81K
Hohl Benjamin
6 Mar 2026
CHIEF FINANCIAL OFFICER
Sell
10,000
$29.58
$295.84K
Collins Helen Louise
17 Feb 2026
CHIEF MEDICAL OFFICER
Sold after exercise
45,000
$26.17
$1.18M
Heyman Richard A.
17 Feb 2026
Director
Sold on a plan indirect
1,230
$26.18
$32.20K
Lyssikatos Joseph P
6 Feb 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
5,000
$29.04
$145.22K
Heyman Richard A.
20 Jan 2026
Director
Sold on a plan indirect
718
$26.96
$19.35K
Heyman Richard A.
20 Jan 2026
Director
Sold on a plan indirect
512
$26.46
$13.55K
Lyssikatos Joseph P
20 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
14,509
$26.90
$390.28K
Lyssikatos Joseph P
20 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
5,491
$26.37
$144.81K
Heyman Richard A.
9 Jan 2026
Director
Sold on a plan indirect
4,285
$25.00
$107.13K
Lyssikatos Joseph P
9 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
50,000
$29.13
$1.46M
Lyssikatos Joseph P
9 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
41,198
$24.90
$1.03M
Patel Anish
9 Jan 2026
CHIEF OPERATING OFFICER
Sold on a plan indirect
243
$28.50
$6.93K
Patel Anish
9 Jan 2026
CHIEF OPERATING OFFICER
Sold on a plan indirect
48,057
$27.98
$1.34M
Heyman Richard A.
8 Jan 2026
Director
Sold on a plan indirect
8,015
$25.04
$200.66K
Heyman Richard A.
8 Jan 2026
Director
Sold on a plan indirect
1,620
$25.00
$40.50K
Lyssikatos Joseph P
8 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
33,802
$24.92
$842.47K
Lyssikatos Joseph P
8 Jan 2026
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
7,500
$20.13
$150.96K
Hohl Benjamin
22 Dec 2025
CHIEF FINANCIAL OFFICER
Exercised, kept
13,000
$2.48
$32.24K
Lyssikatos Joseph P
19 Dec 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
5,000
$16.84
$84.21K
Kunkel Lori Anne
17 Dec 2025
Director
Exercised, kept
15,958
$1.12
$17.87K
Patel Anish
8 Dec 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
1,705
$21.78
$37.13K
Patel Anish
8 Dec 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
4,958
$20.76
$102.94K
Lyssikatos Joseph P
19 Nov 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
492
$23.09
$11.36K
Lyssikatos Joseph P
19 Nov 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
12,008
$22.30
$267.79K
Kintz Samuel
17 Nov 2025
PRESIDENT AND CEO
Sold on a plan indirect
12,500
$21.82
$272.74K
Patel Anish
7 Nov 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
613
$17.94
$11.00K
Patel Anish
7 Nov 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
6,054
$17.35
$105.04K
Lyssikatos Joseph P
20 Oct 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
12,500
$22.08
$276.03K
Kintz Samuel
17 Oct 2025
PRESIDENT AND CEO
Sold on a plan indirect
12,500
$21.33
$266.65K
Patel Anish
7 Oct 2025
CHIEF OPERATING OFFICER
Sold on a plan indirect
6,667
$20.10
$133.99K
Hohl Benjamin
29 Sep 2025
CHIEF FINANCIAL OFFICER
Sold after exercise
3,250
$20.40
$66.29K
Kintz Samuel
26 Sep 2025
PRESIDENT AND CEO
Sold on a plan indirect
3,700
$20.06
$74.23K
Lyssikatos Joseph P
26 Sep 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
4,000
$20.25
$81.01K
Kintz Samuel
23 Sep 2025
PRESIDENT AND CEO
Sold on a plan indirect
2,800
$20.03
$56.08K
Lyssikatos Joseph P
23 Sep 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
1,500
$20.03
$30.05K
Kintz Samuel
19 Sep 2025
PRESIDENT AND CEO
Sold on a plan indirect
1,000
$20.25
$20.25K
Lyssikatos Joseph P
19 Sep 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
2,130
$20.02
$42.63K
Lyssikatos Joseph P
19 Sep 2025
CHIEF SCIENTIFIC OFFICER
Sold on a plan indirect
4,870
$19.11
$93.06K
Kintz Samuel
17 Sep 2025
PRESIDENT AND CEO
Sold on a plan indirect
5,000
$19.09
$95.47K

What was left out

Form 4 filings counted 55
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 2
Sales on a Rule 10b5-1 plan 41
Sales straight out of an exercise 31
Sales at will 7
Transactions with no price 0
Shares from compensation/vesting 441,843
History held since 16 Mar 2020